Invivyd announced positive Phase 1/2 clinical trial data for VYD2311, its next-generation monoclonal antibody designed to prevent and treat COVID-19. The trial demonstrated a favorable safety profile across all doses and administration routes (IV, subcutaneous, and intramuscular). Importantly, VYD2311 exhibited a long half-life, with serum concentrations remaining high six months after a single dose, particularly with intramuscular administration (half-life of 76 days).
This extended half-life positions VYD2311 as a potentially potent, long-acting prophylactic against COVID-19, offering protection for potentially multiple quarters, exceeding the durability of current vaccines. The convenient intramuscular dosing route eliminates the need for intravenous infrastructure, significantly enhancing accessibility and patient convenience, particularly for vulnerable populations like the immunocompromised and the elderly. Furthermore, this extended protection aligns with the increasing need for durable preventative measures against evolving COVID-19 variants.
Dose modeling suggests that VYD2311 could provide superior protection compared to current vaccines, especially through quarterly intramuscular or subcutaneous injections. The intramuscular route demonstrates efficacy comparable to high-dose intravenous administration for prevention, while high-dose intravenous VYD2311 could provide extended viral suppression for treating active infections. This versatility in administration and application broadens the potential use cases for VYD2311.
The positive Phase 1/2 data and planned discussions with the FDA in Q3 2025 pave the way for potential regulatory approval of VYD2311 for both prevention and treatment of COVID-19. This could represent a significant advancement in COVID-19 management, providing a much-needed long-acting prophylactic option and potentially a more effective treatment strategy. The data suggest that VYD2311 could become a vital tool in mitigating the ongoing impact of COVID-19.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
